Optimizing the Treatment of Transplant- Eligible Patients in Multiple Myeloma
|
|
- Darcy Robertson
- 8 years ago
- Views:
Transcription
1 Optimizing the Treatment of Transplant- Eligible Patients in Multiple Myeloma Wednesday, April 10 th, 2013 Chair: Dr. Ade Olujohungbe MD, FRCP, FRCPath Speaker: Dr. Joseph Mikhael MD, MEd, FRCPC, FACP To edit footers: "insert tab>header and footer" and apply to all 0
2 House Keeping
3 Steps in AUTOTRANSPLANTATION (ASCT)
4 Uptake of BMT in Patients Diagnosed with Multiple Myeloma in Manitoba Year Transplanted Not transplanted Total (7.69) 24 (92.31) 26 (8.23) (5.88) 16 (94.12) 17 (5.38) (5.26) 18 (94.74) 19 (6.01) (36.36) 7 (63.64) 11 (3.48) (33.33) 8 (66.67) 12 (3.80) (26.67) 11 (73.33) 15 (4.75) (31.82) 15 (68.18) 22 (6.96) (42.86) 12 (57.14) 21 (6.65) (57.89) 8 (42.11) 19 (6.01) (35.00) 13 (65.00) 20 (6.33) (50.00) 10 (50.00) 20 (6.33) (53.33) 7 (46.67) 15 (4.75) (52.38) 10 (47.62) 21 (6.65) (57.89) 8 (42.11) 19 (6.01) (42.86) 12 (57.14) 21 (6.65) (50.00) 9 (50.00) 18 (5.70) (45.00) 11 (55.00) 20 (6.33) Total 117 (37.03) 199 (62.97) 316 (100.00)
5 Overall survival of patients diagnosed with multiple myeloma, in Manitoba, between 1993 and 2009 Survival Probability Kaplan-Meier survival estimates Time (months) N= 316 entire cohort; median survival 90 s= months, 00 s =42.30 months. Log rank P value =
6 Joseph Mikhael, MD, MEd, FRCPC, FACP Consultant Hematologist and Associate Professor of Medicine Scottsdale clinic Arizona and Mayo college of Medicine. Specialist interest in plasma cell disorders, namely multiple myeloma, amyloidosis and Waldenstrom s macroglobulinemia. Principal investigator of many clinical trials,. Other interests pharmaco-economics, communication skills and supportive care in cancer. Medical school and internal medicine training at the University of Ottawa, Canada. Hematology training at the University of Toronto. Masters degree in education. Multiple Myeloma fellowship at Princess Margaret Hospital. Staff physician at the Princess Margaret Hospital and Toronto General Hospital when he moved to Arizona to work at the Mayo Clinic. Associate Chair of Education for the Department of Medicine. Vice-Chair of Education for the division of Hematology-Oncology. program director of the Hematology-Oncology Fellowship Training Program at Mayo Clinic Arizona. vice-chair of the Graduate Education Committee.
7 Canada s secret import to the USA.
8 Enjoyable program!
9 Learning Objectives Through a review of the most recent evidence and sharing of patient experience, this educational program will endeavor to: 1. Review current best practices in the treatment of patients with Multiple Myeloma prior to receiving a stem cell transplant 2. Explore the role of novel strategies post-transplant in achieving better patient outcomes to treatment 3. Discuss the management and optimal treatment sequencing for patients who have relapsed following a stem cell transplant
10 Please indicate your profession: a) Hematologist/Oncologist b) Nurse c) Pharmacist d) Industry e) Other
11 Please indicate your practice setting: a) Teaching/Academic based b) Community based c) Industry d) Other
12 How many Multiple Myeloma patients do you see in a month (average)? a) None b) 1 5 c) 6 10 d) e) More than
13 Over the past 12 months, what percentage of your newly diagnosed Multiple Myeloma patients received high dose chemotherapy followed by a stem cell transplant (SCT)? a) 0-25% b) 26-50% c) 51-75% d) %
14 What is the most important consideration when selecting an induction regimen for your frontline SCT eligible patients? a) Achieving a VGPR or better b) Stem-cell mobilization c) Overall survival (OS) d) Progression free survival (PFS) e) Tolerability
15 What induction regimen do you use/prefer for your front-line SCT eligible patients? a) Vel-Dex b) Vel-Rev-Dex c) CyBorD d) High dose Dex e) Other
16 Are you able to confidently describe the difference between consolidation and maintenance therapy, in the post-transplant setting? a) Yes b) No c) Not quite
17 What type of therapy are you currently using in your SCT eligible patients post-transplant? a) Consolidation alone b) Maintenance alone c) Consolidation followed by maintenance d) None
18 What regimen do you use/prefer for your SCT eligible patients for consolidation posttransplant? a) Thalidomide based b) Velcade based c) Revlimid based d) Other e) None
19 What regimen do you use/prefer for your SCT eligible patients for maintenance posttransplant? a) Thalidomide based b) Velcade based c) Revlimid based d) Other e) None
20 What is the main barrier to using some form of therapy post-transplant in your SCT eligible patients? a) Limited availability/coverage b) Not enough clinical data to support benefits c) Limited familiarity and/or comfort d) Tolerability issues e) Other
21 What is the most important consideration when selecting a treatment at 1 st relapse for your SCT eligible patients? a) Achieving a complete response (CR) b) Tolerability c) Overall survival (OS) d) Progression free survival (PFS) e) Duration of response to front-line treatment
22 Optimizing the Treatment of Transplant- Eligible Patients in Multiple Myeloma CBMTG Symposium April 10, 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC, FACP Staff Hematologist, Mayo Clinic Arizona
23 Objectives 1. Review current best practices in the treatment of patients with Multiple Myeloma prior to receiving a stem cell transplant 2. Explore the role of novel strategies posttransplant in achieving better patient outcomes to treatment 3. Discuss the management and optimal treatment sequencing for patients who have relapsed following a stem cell transplant
24 Treatment sequence NEW Thal/Dex VD Rev/Dex CyBorD VTD VRD SCT VD/VRD Nothing Thalidomide? Bortezomib? Lenalidomide? Bortezomib Lenalidomide Thalidomide Carlfilzomib Pomalidomide Elotuzumab HDAC Bendamustine Front line treatment Maintenance Relapsed Induction Consolidation Post consolidation Rescue OLD VAD DEX SCT Nothing Prednisone Thalidomide Few options
25 Survival probability Molecular Prognostic Model t(4;14) t(14;16) -17p13 All others including t(11;14) Months P<0.001 Poor Intermediate Good 24.7 mos 42.3 mos 51.0 mos Fonseca et al Blood 101:4569, 2003
26 msmart 2.0: Classification of Active MM High-Risk Intermediate-Risk* Standard-Risk* FISH Del 17p t(14;16) t(14;20) GEP High risk signature FISH t(4;14) Cytogenetic Deletion 13 or hypodiploidy PCLI >3% All others including: Hyperdiploid t(11;14)** t(6;14) Mikhael et al Mayo Clinic Proceedings April 2013
27 msmart 2.0: Classification of Active MM High-Risk 20% Intermediate-Risk 20% Standard-Risk 60% FISH Del 17p t(14;16) t(14;20) GEP High risk signature FISH t(4;14)* Cytogenetic Deletion 13 or hypodiploidy PCLI >3% All others including: Hyperdiploid t(11;14) t(6;14) 3 years 4-5 years 8-10 years
28 Case # 1 58 yo man with 4 month history of back pain Diagnosed with MM: 42% plasmacytosis t(11;14) and no high risk features IgG kappa (m spike 42) with elevated light chains (48 gm/dl) Anemic (Hb 102), ISS 2, Cr mildly elevated How will you treat him?
29 QUESTION #1 What would be your preferred option? 1. Bortezomib (1,4,8,11) and dexamethasone 2. Weekly Bortezomib and dexamethasone 3. CyBorD (Weekly Cyclophosphamide, bortezomib, dexamethasone) 4. Lenalidomide and dexamethasone 5. Bortezomib, lenalidomide, dexamethasone
30 High Risk msmart Off-Study Transplant Eligible Intermediate Risk Standard Risk VRD x 4 Induction with CyBorD 4 cycles of Rd a or CyBorD ASCT, especially if not in CR VRD maintenance for minimum of 1 year Autologous stem cell transplant (ASCT) Bortezomib based consolidation for minimum of 1 year Collect Stem Cells b Autologous stem cell transplant (ASCT) Continue Rd Consider Lenalidomide maintenance* Mikhael et al Mayo Clinic Proceedings April 2013
31 msmart Off-Study Transplant Ineligible High Risk Intermediate Risk Standard Risk* VRd* MP + weekly Bortezomib** or weekly CyBorD Rd b,c Bortezomib maintenance Observation Mikhael et al Mayo Clinic Proceedings April 2013
32 Randomized Phase 3 Trials Trial Rajkumar Regi men No. of pts ORR (%) CR plus VGPR (%) PFS - Median P value for PFS RD Rd year OS (%) Harousseau VAD VD Cavo TD VTD NR
33 Results RD vs. Rd RD Rd CR + PR 79% 68% 1 year OS 87% 96% Grade 3 or worse AE 52% 35% RD did not result in superior TTP, PFS, or OS compared to Rd OS at 1-year was significantly better with Rd than RD, resulting in early closure of the trial Rajkumar et al, 2010.
34 Once Versus Twice Weekly Bortezomib in CyBorD for Newly Diagnosed Myeloma
35 CyBorD Method 63 patients enrolled Cohort 1: (standard bortezomib dosing) (n=33) Cohort 2: (weekly bortezomib) (n=30) 1 st goal - 40%>VGPR 2 nd goal safety, survival, stem cell collection Newly diagnosed symptomatic MM ECOG < 2 Platelets > 100,000, ANC > 1,000, Cr < 3.5 Acyclovir, quinolone antibiotic
36
37 Weekly versus Biweekly CYBOR-D as Induction Therapy Reeder C, et al. Leukemia 2009; 23: ; Reeder CB, et al. Blood 2010; 115:
38 Once Weekly Subcutanous Bortezomib with Cyclophosphamide and Dexamethasone Is Well Tolerated and Effective As Initial Treatment in Symptomatic Multiple Myeloma David Simpson, FRACP, FRCPA, MBChB, James Liang, MBChB, Ross Henderson, MBChB, PhD, FRACP, FRCPA, Merit Hanna, MBChB, FRCPA and Eileen Merriman, MBChB, FRACP, FRCPA Simpson D. et al. ASH 2012, A4049
39 Response After Each Cycle Weekly subcutaneous Bortezomib is well tolerated, and has high patient acceptance. Dose limiting neuropathy is rare, and responses are high when used in combination with CyBorD or VTD Simpson D. et al. ASH 2012, A4049
40 The NEW CyBorD All three drugs given weekly Cyclophosphamide 300mg/m2 PO Bortezomib 1.5 mg/m2 IV or SQ Dexamethasone 40mg PO We consider one cycle a 4 week course No week off Less neuropathy, more convenience, equal efficacy Always give viral prophylaxis Comment I see CyBorD as a slight modification to VMP
41 Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study Shaji Kumar, MD, Ian W. Flinn, MD, PhD, Paul G Richardson, MD, Parameswaran Hari, MD, Natalie Scott Callander, MD, Stephen J. Noga, MD, PhD, A. Keith Stewart, MD, Jonathan Glass, MD, FACP, Robert M. Rifkin, MD, Jeffrey L Wolf, MD, Jose Estevam, BS, George Mulligan, PhD, Hongliang Shi, MS, Iain J. Webb, MD, FRCPC and S. Vincent Rajkumar, MD Kumar et al, ASH 2010 (Abstract 621)
42
43
44
45 EVOLUTION Adverse Events VDCR n = 48 VDR n = 42 VDC n = 33 VDC-mod n = 17 Hematological AEs, n (%) Neutropenia 21 (44) 4 (10) 10 (30) 4 (24) Febrile neutropenia 4 (8) 1 (2) 2 (6) 0 Thrombocytopenia 7 (15) 5 (12) 4 (12) 0 Leukopenia 6 (13) 0 3 (9) 1 (6) Anemia 4 (8) 3 (7) 0 2 (12) Lymphopenia 4 (8) 1 (2) 4 (12) 0 Nonhematological AEs Pneumonia 2 (4) 2 (5) 0 1 (6) Neuropathy 6 (13) 7 (17) 3 (9) 3 (18) Fatigue 8 (17) 3 (7) 1 (3) 0 Diarrhea 3 (6) 1 (2) 1 (3) 1 (6) Nausea 0 1 (2) 0 0 Thromboembolism 1 (2) Constipation Hyperglycemia Summary At least one grade 3 or above AE 40 (83) 32 (76) 26 (79) 15 (88) At least one drug-related grade 3 or above AE 38 (79) 25 (60) 20 (61) 12 (71) At least one grade 3 or above hematological AE 28 (58) 11 (26) 17 (52) 5 (29) AE resulting in discontinuation 10 (21) 8 (19) 4 (12) 1 (6)
46
47
48 Is there an evil side to treating with all drugs?
49 Dollar Cost of Regimens (BSA 2 m 2 ) per 28 days (per year) 1. VRD $23,000 (276K) 2. VTD $22,000 (264K) 3. PAD $14,400* (173K) 4. CyBorD (weekly) $ 9,200 (110K) 5. Rd $ 9,000 (108K) 6. TD $ 8,200 ( 98K)
50 Back to Case #1 Treated with weekly CyBorD After 4 cycles achieves PR (with m spike down from 42 to 12) You decide to send to ASCT Post ASCT at day 100, M spike now at 6 (just short of VGPR) What will you do?
51 QUESTION #2 What would you do post ASCT? 1. No further therapy, wait and watch 2. Second ASCT 3. Consolidation with more bortezomib 4. Maintenance therapy with lenalidomide 5. Maintenance therapy with bortezomib
52 1. Nada therapy 2. 2 nd ASCT Options now 3. Maintenance lenalidomide or bortezomib 4. Consolidation thalidomide/lenalidomide or bortezomib Remember the difference between them and the historical perspective
53 Phase 3: bortezomib consolidation versus no consolidation following ASCT Induction + single or double ASCT (n=404) Randomization (3 months post-asct) (n=392) Bortezomib (n=149) Observation (n=150) 1.3 mg/m 2 day 1, 4, 8, 11 for two 3-week cycles then day 1, 8, 15 for four 4-week cycles (total 20 injections over 21 weeks) Mellqvist et al. IMW 2011
54 Progression free survival 20 mo 27 mo bortezomib control p=0.037 Mellqvist et al. IMW 2011
55 Cavo et al. Blood 2012;120:9-19
56 Phase 3: VTD vs VD Efficacy VTD TD p After Induction > ncr 33.1% 13.7% < After Double ASCT > ncr 63.1% 54.7% After Consolidation > ncr 73.1% 60.9% Overall, the probability of upgrading from less than CR before consolidation therapy to CR after consolidation was significantly higher in patients receiving VTD (25 of 82 patients, 30.5%) than in those receiving TD (16 of 96 patients, 16.7%; p =.030). Most of the patients who improved to CR after VTD consolidation therapy were in ncr (44%) or VGPR (52%) before starting consolidation therapy. Cavo et al. Blood 2012;120:9-19
57 VTD VTD TD M.Cavo, Lancet 2010, 376,
58 Phase 3: VTD vs TD (GIMEMA study) Impact of VTD consolidation Per-protocol analysis: n=321, received entire treatment program VTD TD p CR post-consolidation 61% 47% Upgrade to CR post-consolidation 30.4% 16.6% Landmark analysis from start of consolidation (30 months median follow up) 3-yr probability of relapse or progression 38% 52% yr PFS 60% 48% Superior PFS with VTD vs TD consolidation retained across poor prognosis subgroups: t(4;14) and/or del(17q), del(13q) β 2 -M >3.5 mg/l, LDH >190 U/L, ISS stage 2 and 3 Cavo et al. Blood 2012;120:9-19
59 Clinical Impact of VTD Consolidation in VGPR Patients After ASCT Responses after ASCT VGPR 85% CR 15% Responses after VTD VGPR 49% CR 49% 15% 85% 49% 49% VGPR CR Ladetto et al. J Clin Oncol 2010;28:
60 Phase 3: VTD vs TD (GIMEMA study) Impact of VTD consolidation No OS difference between two groups Both treatments well tolerated Frequency of grade 3/4 AEs comparable in both groups 9.3% VTD, 8.6% TD PN with VTD: 0.6% Skin rash, DVT: 0.6% in each group Patients treated with VTD received 93% of planned doses of bortezomib and thal Cavo et al. ASH 2011 (Abstract 1871), oral presentation
61 Serious AEs and grade 3 or 4 AEs reported in at least 2% of patients during induction Cavo et al. Lancet 2010;376:
62 Phase 2: VRD induction, ASCT, VRD consolidation, lenalidomide maintenance (IFM 2008) Patients (n=31) % After VRD induction After ASCT After VRD consolidation After Len maintenance (3 cycles) (2 cycles) (12 months) scr CR VGPR Improvement in responses Consolidation: upgraded response in 26% Len maintenance: no improvement in response rate Roussel et al. ASH 2011 (Abstract 1872), poster presentation
63 HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High- Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM) Pieter Sonneveld, Ingo Schmidt-Wolf, Bronno van der Holt *, Laila el Jarari, Uta Bertsch, Hans Salwender, Sonja Zweegman, Edo Vellenga, Joerg Schubert, Igor Wolfgang Blau, Asiong Jie, Berna Beverloo, Dirk Hose, Anna Jauch, Helgi van de Velde, Martijn Schaafsma, Walter Lindemann, Marie Jose Kersten, Ulrich Duehrsen, MD, Michel Delforge, Katja Weisel, Sandra Croockewit, Hans Martin, Shulamit Wittebol, Christof Scheid, Gerard Bos, Marinus van Marwijk-Kooy, Pierre Wijermans, Henk Lokhorst and Hartmut Goldschmidt Sonneveld et al ASH 2010, (abstract 40) Oral presentation
64 ASH 2010 Phase III: PAD vs VAD induction, HDM and bortezomib or thalidomide maintenance HOVON 65 MM / GMMG-HD4 study MM Stage II or III, Age n=744, median age 57 Randomization n=373 3 x VAD CAD + GCSF 3 x PAD CAD + GCSF n=371 PAD: Bortezomib 1.3 mg/m 2 Doxorubicin 9 mg/m 2 Dex 40 mg MEL PBSCT MEL PBSCT Depending on local policy for patients PR MEL PBSCT Allogeneic Tx Depending on local policy for patients PR MEL PBSCT Thalidomide 50 mg/day for 2 years maintenance Bortezomib 1.3 mg/m 2 / 2 weeks for 2 years maintenance
65 ASH 2010 Response data VAD PAD P-value Response after induction (%) CR/nCR VGPR <0.001 PR < Response after HDM 1 (%) CR/nCR < VGPR <0.001 PR < Response on protocol (%) CR/nCR <0.001 VGPR PR
66 ASH 2010 Achievement of best response during maintenance therapy (%) Response after HDM (%) PR VGPR ncr Arm A (Thalidomide) Arm B (Bortezomib) Improvement of Response during Maintenance < PR PR 4 1 < VGPR VGPR < ncr ncr < CR CR 10 12
67 ASH 2010 Adverse effects during 2 years maintenance thalidomide (%) bortezomib (%) WHO CTC grade Infections GI Neurotoxicity (PN) Constitutional
68 ASH 2010 Feasibility of maintenance treatment VAD arm Thalidomide % PAD arm Bortezomib % Started M (n) At 6 months At 12 months At 18 months At 24 months 29 49
69 Progression-free and overall survival 100 (A) 100 (B) Cumulative percentage A: VAD B: PAD A: VAD B: PAD Cox LR At risk: N P= F (adj. ISS) B: PAD A: VAD months Cumulative percentage A: VAD B: PAD A: VAD B: PAD Cox LR At risk: N F P = B: PAD A: VAD mo (C) 100 Cumulative percentage A: VAD B: PAD A: VAD B: PAD Cox LR At risk: N D P = B: PAD A: VAD mo A: PFS all B: PFS censored for allo-sct C: OS Median follow up: 48 months
70
71
72
73 Phase III Intergroup Study of Lenalidomide Vs Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation for MM: CALGB Registration Restaging Days Randomization S-D Stage 1-3, < 70 years >2 cycles of induction Attained SD or better 1 yr from start of therapy >2 x 10 6 CD34 cells/kg Mel 200 ASCT CR PR SD Placebo Lenalidomide* 10 mg/d with (5 15 mg) Patient stratification based on diagnostic β-2m and thalidomide and lenalidomide therapy during induction *provided by Celgene Corp, Summit, NJ McCarthy, P. L. et al. NEJM 2012
74 IFM : Study design Phase III randomized, placebo-controlled trial N= 614 patients, from 78 centers, enrolled between 7/2006 and 8/2008 Patients < 65 years, with non-progressive disease, 6 months after ASCT in first line Randomization: stratified according to Beta-2m, del13, VGPR Arm A= Placebo (N=307) Consolidation: Lenalidomide alone 25 mg/day p.o. days 1-21 of every 28 days for 2 months Arm B= Lenalidomide (N=307) until relapse mg/d until relapse Primary end-point: PFS. Secondary end-points: CR rate, TTP, OS, feasibility of long-term lenalidomide. ASCT = autologous stem cell transplant.
75 Efficacy of Maintenance CALGB trial Placebo Lenalidomide P- value TTP (months) < yr. OS (%) IFM trial PFS (months) < yr. OS (%) McCarthy et al. And Attal et al NEJM. May 10, 2012
76 Toxicity of Maintenance CALGB trial Placebo Lenalidomide P- value Grade III/IV hematological <0.001 SPM (n) 6 18 IFM trial Grade III/IV hematological <0.001 VTE SPM 1.2/100 PY 3.1/100 PY McCarthy et al. And Attal et al NEJM. May 10, 2012
77 Dr. Joe s Conclusions Lenalidomide maintenance does indeed prolong PFS but not OS PFS inadequate endpoint for maintenance study placebo vs active drug design Consider QOL, AEs, and COST! Len maintenance not yet proved to be superior to salvage Len One immature, (weakly) positive study does not change practice esp. if 2 nd more mature trial negative
78 Dr. Joe s Conclusions Contd. Somewhat biased to len responders However, this is an NCCN approved option The Second Primary Malignancy issue remains unclear, but likely less worrisome than first thought, and has a lot to do with melphalan risk grows at 2 years BUT, we must be vigilant to monitor Underscores the need of open communication with patient Many other maintenance options now being explored, esp with bortezomib
79 Maintenance Therapy - Practical Consider consolidation if responding Consider lenalidomide maintenance in standard risk patients not in VGPR or better Don t use maintenance therapy in patients with indolent myeloma (long standing MGUS/smoldering or slow growers We suggest bortezomib maintenance/consolidation in intermediate and high risk patients
80 Case #2 What if it were the same patient BUT: 1. They are in CR 2. They have t(4;14)
81 QUESTION #3 What would you do post ASCT if in CR? 1. No further therapy, wait and watch 2. Second ASCT 3. Consolidation with more bortezomib 4. Maintenance therapy with lenalidomide 5. Maintenance therapy with bortezomib
82 QUESTION #4 What would you post ASCT if t(4;14)? 1. No further therapy, wait and watch 2. Second ASCT 3. Consolidation with more bortezomib 4. Maintenance therapy with lenalidomide 5. Maintenance therapy with bortezomib
83 Case #3 Same original case of now 62 yo man with standard risk MM Had CyBorD with PR, ASCT then 4 more cycles of CyBorD achieving near complete remission Monitored for 3 years Now he is starting to relapse Initial thoughts? Ask yourself 10 questions
84 QUESTION #5 What would you do for relapse? 1. Go back to CyBorD 2. Class switch and use lenalidomide 3. Plan to go to 2 nd ASCT 4. 1 and and 3
85 RELAPSE With prolonged survival in most patients with myeloma, relapse therapy is more important than ever Approach must now take into account long term thinking Overall approach must be: Evidence based Rational Individualized to patient I don t really believe in standard second line therapy A strategy to choose the best therapy needs to address multiple issues Ask yourself the following 10 questions:
86 Question #1: Do I need to treat the patient? Spectrum of MGUS, Asymptomatic (smoldering) MM and true MM Recall the importance of Calcium Renal insufficiency Anemia Bone Disease Consider the pace of the relapse Other variables learned from newly dx MM (plasmacytosis >60% and FLC over 100)
87 Question #2: What did I use the last time? Depth of response How rapidly and successfully did it work CR, VGPR, PR, MR, SD Duration of Response How long did it last? If depth and duration reasonable, consider retreating with same regimen knowing it will be less effective Corollary is Class Switch
88 Question #3: How well tolerated was the previous therapy? Key areas of tolerability Neuropathy Cytopenias with sequelae Fatigue Other Did it lead to dose reductions or discontinuation? To what extent did it impair quality of life?
89 Question #4: Have I employed the Big Five? Hopefully sequentially Thal little cytopenias, ok in renal dz Neuropathy, fatigue, thrombosis, constipation Bortezomib manageable cytopenias, ok in renal dz Neuropathy, IV/SC administration (WEEKLY)
90 Question 4 contd. Lenalidomide little neuropathy Fatigue, may affect stem cell collection Concern of MDS or secondary malignancies Carfilzomib novel proteasome (FDA Approved July 2012) Must have had bortezomib + thal or len prior AND relapsing Issues include tumor lysis, SOB, possible cardiac issues
91 Question 4 contd. Pomalidomide (FDA approved February 2013) Similar toxicity profile to lenalidomide Slightly less myelosuppressive
92 Question #5: Is Salvage Transplant an Option? With increasing interest in novel agents, salvage ASCT may be forgotten Potential long term benefit (esp in standard risk) with long PFS and drug holiday Viable option as SECOND ASCT if: 1. Evidence of response first time 2. PFS of greater than 2 years 3. Well tolerated first time Repeat ASCT yields about 50-75% PFS of first
93 Question #6: Have I employed the Add On Agents? Several agents have demonstrated ability to amplify effect of the Big Three Steroids dexamethasone or prednisone (weekly or alt day) Cyclophosphamide orally, 300mg/m2 weekly very well tolerated Doxil usually with bortezomib PS: Don t forget Melphalan!
94 Question #7: Does Risk Stratification affect my choice? Please consider repeat marrow (with cytogenetics) at point of relapse High: likely combination and for prolonged period Intermediate: likely bortezomib based Standard: fewer drugs at once, more likely sequential
95 Question #8: What other patient factors influence choice? Several factors will sway choice: Age Renal insufficiency Aggressivity of relapse Cost Convenience Steroid status
96 Question #9: Should I consider multiple novel agent use? Potential use of an agent even if patients failed previously Defn: Progression on agent or within 60 days Usually in late or very aggressive relapse Most used combinations: VRD (bortezomib, lenalidomide, dex) VTD (bortezomib, thalidomide, dex) VDT-PACE (platinum, adriamycin, cyclophosphamide, etoposide)
97 Question #10: Is a Clinical Trial an Option? Depending on location and proximity, a host of options exist Over 160 trials listed on clinicaltrials.gov Initial therapy, transplant, relapse, supportive care, bone disease, phase 1. Most promising agents: novel proteasome inhibitors, monoclonal antibodies (esp daratumumab), KSP inhibitors and anti BAFF
98 60 Single-Agent Activity of 39 Drugs Tested in Multiple Myeloma 50 PR (%) Provided by Dr. Keith Stewart
99
100 Implications 1. In high risk disease multiple genomic clones (combination chemotherapy a necessity) 2. In high risk disease genome is unstable (avoid DNA damaging agents?) 3. Re-Emergence of drug sensitive clones (Once resistant not always resistant)
101 Thank You! me anytime:
102 What is the most important consideration when selecting an induction regimen for your frontline SCT eligible patients? a) Achieving a VGPR or better b) Stem-cell mobilization c) Overall survival (OS) d) Progression free survival (PFS) e) Tolerability
103 Are you able to confidently describe the difference between consolidation and maintenance therapy, in the post-transplant setting? a) Yes b) No c) Not quite
104 If funding was available, what type of therapy would you consider using in your SCT eligible patients post-transplant? a) Consolidation alone b) Maintenance alone c) Consolidation followed by maintenance d) None e) Not sure
105 If funding was available, in which patients would you consider using consolidation therapy following transplant? a) All patients b) Selected patients c) None d) Not sure
106 If funding was available, in which patients would you consider using maintenance therapy following transplant? a) All patients b) Selected patients c) None d) Not sure
107 What is the most important consideration when selecting a treatment at 1 st relapse for your SCT eligible patients? a) Achieving a complete response (CR) b) Tolerability c) Overall survival (OS) d) Progression free survival (PFS) e) Duration of response to front-line treatment
108
109
Treatment results with Bortezomib in multiple myeloma
Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of
More informationSTEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationMultiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, 2008. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida
Multiple Myeloma: Novel Agents Robert A. Kyle, M.D. Germany June 28, 2008 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Multiple Myeloma Untreated Initial Therapy Transplant eligible Multiple
More informationCure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
More informationMultiple Myeloma Therapy Doublet, Triplet, and beyond October 2013 The IV. International Eurasian Congress of Hematology Rafat Abonour, M.D.
Multiple Myeloma Therapy Doublet, Triplet, and beyond October 2013 The IV. International Eurasian Congress of Hematology Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm,
More informationCurrent Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More informationMultiple Myeloma. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida CP1123175-1
Multiple Myeloma 8 th Annual Living with Myeloma Conference New Developments in Multiple Myeloma Treatment Scottsdale, AZ March 22, 2014 Robert A. Kyle, MD Scottsdale, Arizona Rochester, Minnesota Jacksonville,
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More informationMULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology
MULTIPLE MYELOMA Review & Update for Primary Care Dr. Joseph Mignone 21st Century Oncology OVERVIEW Identify the diagnostic criteria for multiple myeloma Compare first & second line therapies, using data
More informationFuture strategies for myeloma: An overview of novel treatments In development
Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide
More informationTreating myeloma. Dr Rachel Hall Royal Bournemouth Hospital
Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens
More informationOutline. Question 1. Question 2. What is Multiple Myeloma? Andrew Eisenberger, MD
Outline A Disease Overview June 3, 2013 Andrew Eisenberger, MD Assistant Professor of Medicine Hematology/Oncology Columbia Presbyterian Medical Center Introduction Epidemiology/Risk Factors Clinical Features/Diagnostic
More informationBendamustine for the fourth-line treatment of multiple myeloma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard
More informationPersonalized, Targeted Treatment Options Offer Hope of Multiple Myeloma as a Chronic Disease
/publications/targeted-therapy-news/2012/november-2012/personalized-targeted-treatment-options- Offer-Hope-of-Multiple-Myeloma-as-a-Chronic-Disease Personalized, Targeted Treatment Options Offer Hope of
More informationShaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological
An update on the management of multiple myeloma and amyloidosis Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological malignancy in this country affecting nearly
More information2014; 5(3): 248-252. doi: 10.7150/jca.8541 Research Paper
248 Ivyspring International Publisher Journal of Cancer 2014; 5(3): 248-252. doi: 10.7150/jca.8541 Research Paper Partial Response at Completion of Bortezomib- Thalidomide-Dexamethasone (VTd) Induction
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationMULTIPLE MYELOMA Treatment Overview
MULTIPLE MYELOMA Treatment Overview ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION After being diagnosed with multiple myeloma in 1998, Kathy Giusti and her sister Karen Andrews, a successful corporate
More informationREVLIMID and IMNOVID for Multiple Myeloma
REVLIMID and IMNOVID for Multiple Myeloma What is Multiple Myeloma? Multiple myeloma (MM) is a persistent and life-threatening blood cancer that is characterised by tumour proliferation and immune suppression.
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationPro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany
Pro Cure in Multiple Myeloma Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Several hematological malignancies can be cured
More informationMultiple Myeloma. Solving a growing puzzle
Multiple Myeloma Solving a growing puzzle Disclosures Financial I wish. I eat too much. I did ask who the audience would be. Nurses and Doctors Goals 1. Understand the incidence, symptoms, and pathophysiology
More informationStem Cell Transplantation for Multiple Myeloma: Current and Future Status
CONTROVERSIES AND UPDATES IN MULTIPLE MYELOMA Stem Cell Transplantation for Multiple Myeloma: Current and Future Status Sergio Giralt 1 1 Memorial Sloan Kettering Cancer Center, New York, NY High-dose
More informationModern Induction Therapy for Transplant-ineligible Multiple Myeloma Patients: Literature of Review
Modern Induction Therapy for Transplant-ineligible Multiple Myeloma Patients: Literature of Review Dr. Kalita Lohit kumar 1, Dr. Gogoi Pabitra Kamar 2, Dr. Sarma Umesh Ch. 3 1 MS, Assistant Professor,
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationAUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE?
AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE? *Patrizia Tosi Hematology Unit, Department of Oncology and Hematology, Infermi Hospital, Rimini, Italy *Correspondence
More informationWhat's new for the treatment of multiple myeloma and related disorders in 2010? Angela Dispenzieri, M.D.
What's new for the treatment of multiple myeloma and related disorders in 2010? Angela Dispenzieri, M.D. The progress being made for the treatment of multiple myeloma has resulted in a significant prolongation
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationFEIST- WEILLER CANCER CENTER MULTIPLE MYELOMA GUIDELINES. Updated December, 2011. Authors: Nebu Koshy, MD. Binu Nair, MD. Gerhard Hildebrandt, MD
FEIST- WEILLER CANCER CENTER MULTIPLE MYELOMA GUIDELINES Updated December, 2011 Authors: Nebu Koshy, MD Binu Nair, MD Gerhard Hildebrandt, MD Reinhold Munker, MD Glenn Mills, MD Mandatory initial tests
More informationMultiple. Powerful thinking advances the cure
Multiple Myeloma Treatment OVERVIEW Powerful thinking advances the cure Powerful thinking advances the cure About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation (MMRF)
More informationMULTIPLE MYELOMA. Version Date: February, 2015
MULTIPLE MYELOMA Version Date: February, 2015 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team synthesis of currently accepted approaches
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007
More informationMULTIPLE MYELOMA. Overview
MULTIPLE MYELOMA Overview Steven R. Schuster, M.D. May 7, 2015 Objectives Give an overview of Multiple Myeloma Everything I know in 15 minutes Explain how genetic information can be used to personalize
More informationBendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line
More informationLong-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma
ORIGINAL ARTICLE LONG-TERM RESULTS OF REV-DEX THERAPY FOR NEWLY DIAGNOSED MYELOMA Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly
More informationMultiple Myeloma Workshop- Tandem 2014
Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone
More informationAsymptomatic or smoldering myeloma with no symptoms and slow growing cancer cells
ESSENTIALS Multiple Myeloma Diagnosed with Multiple Myeloma? It s important to understand everything you can about your diagnosis, possible treatments, and places to go for support and care. Cancer is
More informationUNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
More informationWaldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP
Waldenström Macroglobulinemia: The Burning Questions IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Are my kids going to get this? Familial seen in approximately 5 10% of all CLL patients and can be associated
More informationlenalidomide, 5mg, 10mg, 15mg and 25mg hard capsules (Revlimid ) SMC No. (441/08) Celgene Limited
Resubmission: lenalidomide, 5mg, 10mg, 15mg and 25mg hard capsules (Revlimid ) SMC No. (441/08) Celgene Limited 07 March 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationBackground Information Myeloma
Myeloma FAST FACTS Myeloma, also known as multiple myeloma, is a type of cancer that develops from plasma cells which originate in the bone marrow 1 Myeloma is the second most common type of blood cancer
More informationA Clinical Primer. for Managed Care Stakeholders
reviews therapy Diagnosing, Staging, and Treating Multiple Myeloma: A Clinical Primer for Managed Care Stakeholders by Ralph V. Boccia, MD, FACP, Medical Director, Center for Cancer and Blood Disorders
More informationORIGINAL ARTICLE. European Journal of Haematology ISSN 0902-4441
European Journal of Haematology ISSN 0902-4441 ORIGINAL ARTICLE Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory
More informationTarget Audience. This activity has been designed to meet the educational needs of hematologistoncologists
Target Audience This activity has been designed to meet the educational needs of hematologistoncologists and medical oncologists involved in the care of patients with multiple myeloma 1 Learning Objectives
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationOptimal Sequencing of Treatments for Maximizing Outcomes in Multiple Myeloma
Slide 1 Sergio Giralt, MD: Welcome to the webcourse Optimal Sequencing of Treatments for Maximizing Outcomes in Multiple Myeloma. This educational activity is jointly provided by the Potomac Center for
More informationAutologous stem cell transplantation for multiple myeloma: history and future
REVIEW International Journal of Myeloma 3(2): 55 66, 2013 日 本 骨 髄 腫 学 会 Autologous stem cell transplantation for multiple myeloma: history and future Chihiro SHIMAZAKI 1 Over the last decade, high-dose
More informationUnderstanding Revlimid
Understanding Revlimid International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454 TheIMF@myeloma.org
More informationReview Article Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
Advances in Hematology, Article ID 652395, 12 pages http://dx.doi.org/1.1155/214/652395 Review Article Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma Zeina Al-Mansour and Muthalagu
More informationMultiple Myeloma in HUSM. Dr Azlan Husin HUSM
Multiple Myeloma in HUSM Dr Azlan Husin HUSM Outline Overview Presenting features Progress in myeloma Global HUSM Multiple myeloma is a neoplastic plasma-cell disorder that is characterized by clonal proliferation
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Lenalidomide (Revlimid) for Multiple Myeloma October 22, 2013
pan-canadian Oncology Drug Review Final Economic Guidance Report Lenalidomide (Revlimid) for Multiple Myeloma October 22, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationMULTIPLE MYELOMA TREATMENT OVERVIEW
MULTIPLE MYELOMA TREATMENT OVERVIEW Sponsored by: This activity is supported by independent educational grants from Genentech BioOncology, Merck & Co., Inc., Millennium Pharmaceuticals, Inc., and Novartis
More informationNATIONAL CANCER INSTITUTE. Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
NATIONAL CANCER INSTITUTE Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Basic Trial Information Phase Type Status Age Sponsor Protocol IDs Phase
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationMULTIPLE MYELOMA 1 PLASMA CELL DISORDERS Multiple l Myeloma Monoclonal Gammopathy of Undetermined Significance (MGUS) Smoldering Multiple Myeloma (SMM) Solitary Plasmacytoma Waldenstrom s Macroglobulinemia
More informationHenk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson
DRTUMUMB, a CD38 Monoclonal ntibody Study in dvanced Multiple Myeloma an Open-Label, Dose Escalation Followed by Open-Label Extension in a Single-rm Phase I/II Study bstract #S576 Henk Lokhorst, Torben
More informationAutologous Retransplantation for Patients With Recurrent Multiple Myeloma
Autologous Retransplantation for Patients With Recurrent Multiple Myeloma A Single-Center Experience with 200 Patients Leopold Sellner, MD 1 ; Christiane Heiss 2 ; Axel Benner 2 ; Marc S. Raab, MD 1 ;
More informationcancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146
Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer
More informationMomentum in Multiple Myeloma Treatment
WHITE PAPER Momentum in Multiple Myeloma Treatment Dr. Harish P. Dave, MD, MBA Dr. Ben Manderman, MD Quintiles examines promising new approaches to more effective multiple myeloma treatments. HIGH RESPONSE
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationPhase II: Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Neha Korde, MD, Clinical Investigator Ola Landgren, MD
Phase II: Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Neha Korde, MD, Clinical Investigator Ola Landgren, MD PhD, Principal Investigator Multiple Myeloma Section, NCI/NIH,
More informationIntegrating novel agents into multiple myeloma treatment current status in Switzerland and treatment recommendations
current status in Switzerland and treatment recommendations Christian Taverna a, Mario Bargetzi b, Daniel Betticher c, Jürg Gmür d, Michael Gregor e, Dominik Heim f, Urs Hess g, Nicolas Ketterer h, Erika
More informationIn multiple myeloma, the depth and maintenance of
Continuous therapy with lenalidomide in multiple myeloma by Nizar Bahlis, MD Abstract In multiple myeloma, the depth and maintenance of response to therapy has been shown to correlate with improved survival.
More informationA Science Writer s Guide to Multiple Myeloma
A Science Writer s Guide to Multiple Myeloma 1 A Science Writer s Guide to Multiple Myeloma A Science Writer s Guide to Multiple Myeloma PREFACE Blood cancers and related disorders a serious health risk
More informationContinuing medical education activity in American Journal of Hematology
Continuing medical education activity in American Journal of Hematology CME Editor: Ayalew Tefferi, MD Author: S. Vincent Rajkumar, MD Article Title: Multiple Myeloma: 2012 update on Diagnosis, Risk-stratification
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationMultiple Myeloma and Amyloidosis: Optimism for Heretofore Incurable Diseases
Multiple Myeloma and Amyloidosis: Optimism for Heretofore Incurable Diseases Robert Vescio, MD Director Multiple Myeloma & Bone Metastases Program Samuel Oschin Comprehensive Cancer Center Cedars-Sinai
More informationFocus on the Treatment of Multiple Myeloma
Focus on the Treatment of Multiple Myeloma PRINTER-FRIENDLY VERSION AT CLINICALONCOLOGY.COM SHAJI KUMAR, MD Associate Professor of Medicine Division of Hematology Mayo Clinic Rochester, Minnesota S. VINCENT
More informationTrials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
More information6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic
Follicular and Other Slow Growing Lymphomas Stephen Ansell, MD, PhD Mayo Clinic 1 Learning Objectives Start with an overview of Follicular and other slow growing lymphomas Discuss current and emerging
More informationHealth Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.
Health Disparities in Multiple Myeloma Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Multiple Myeloma Overview Multiple myeloma (MM) is a type of blood cancer that develops
More informationThings You Don t Want to Miss in Multiple Myeloma
Things You Don t Want to Miss in Multiple Myeloma Sreenivasa Chandana, MD, PhD Attending Hematologist and Medical Oncologist West Michigan Cancer Center Assistant Professor, Western Michigan University
More informationMultiple Myeloma F1 蘇 勇 誠 /MA 林 棟 樑 2007-3-28
Multiple Myeloma F1 蘇 勇 誠 /MA 林 棟 樑 2007-3-28 Plasma Cell Disorders Multiple Myeloma Other Disorders Monoclonal gammopathy of undetermined significance (MGUS) Smoldering multiple myeloma (SMM) Solitary
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationFIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS
ORIGINAL ARTICLE FIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS Jakub Radocha, Vladimír Maisnar, Alžběta Zavřelová, Melanie Cermanová,
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationChapter 8. Summary, general discussion and future perspectives
Summary, general discussion and future perspectives 115 Summary Multiple Myeloma (MM) is characterized by a malignant proliferation of monoclonal plasma cells in the bone marrow, clinical presenting by
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY Torben Plesner, Henk Lokhorst, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson
More informationLong Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia
Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationMultiple Myeloma Patient s Booklet
1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore 119228 Email : ncis@nuhs.edu.sg Website : www.ncis.com.sg LIKE US ON FACEBOOK www.facebook.com/ nationaluniversitycancerinstitutesingapore Multiple
More informationMultiple Myeloma: Overview and Therapeutic Approaches
Multiple Myeloma: Overview and Therapeutic Approaches Presented as a Live Webinar Wednesday, August 14, 2013 and Wednesday, September 11, 2013 Planned and conducted by ASHP Advantage and supported by educational
More informationChapter 2. S. Hovenga 1, J.Th.M. de Wolf 1, J.E.J. Guikema 4, H. Klip 2, J.W. Smit 3, C.Th. Smit Sibinga 5, N.A. Bos 4, E.
Chapter 2 Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses; a high incidence of oligoclonal serum immunoglobulins post transplantation S. Hovenga, J.Th.M. de Wolf, J.E.J.
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular
More informationMichael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto
Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory
More informationManagement of multiple myeloma: The changing landscape
Blood Reviews (2007) 21, 301 314 www.elsevierhealth.com/journals/blre REVIEW Management of multiple myeloma: The changing landscape Donna E. Reece * Department of Medical Oncology/Hematology, Princess
More informationPharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans
Pharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans C. Daniel Mullins, PhD Professor Pharmaceutical Health Services Research Department University
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Upfront Therapy in Newly Diagnosed Elderly AML Patients: Is Decitabine (DAC) the new standard? Raoul Tibes, MD, PhD Senior Associate Consultant, Mayo Clinic Arizona Associate Director,
More informationFARYDAK (Panobinostat) for the Treatment of Patients With Previously Treated Multiple Myeloma
CI-1 FARYDAK (Panobinostat) for the Treatment of Patients With Previously Treated Multiple Myeloma Oncologic Drugs Advisory Committee Meeting November 6, 2014 CI-2 FARYDAK (Panobinostat) for the Treatment
More informationLEUCEMIA MIELOIDE ACUTA. A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova
LEUCEMIA MIELOIDE ACUTA A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova Impact of mutational analysis in AML C. Thiede Optimal acute myeloid leukemia therapy in 2012 H. Dombret Acquired
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationHow to treat elderly patients with multiple myeloma: combination of therapy or sequencing
MULTIPLE MYELOMA How to treat elderly patients with multiple myeloma: combination of therapy or sequencing Antonio Palumbo 1 and Francesca Gay 1 1 Divisione di Ematologia dell Università di Torino, Azienda
More informationMultiple myeloma: 2014 Update on diagnosis, riskstratification,
AJH Educational Material Multiple myeloma: 2014 Update on diagnosis, riskstratification, and management AJH S. Vincent Rajkumar* Disease overview: Multiple myeloma accounts for approximately 10% of hematologic
More informationRevving up the Revlimid Debate Lenalidomide as Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant
Revving up the Revlimid Debate Lenalidomide as Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant Sarah M. Villarreal, Pharm.D. PGY2 Hematology/Oncology Pharmacy Resident Department
More informationTherapie des Patienten mit rezidiviertem Multiplem Myelom
DGHO 2014, Hamburg Therapie des Patienten mit rezidiviertem Multiplem Myelom Martin Gramatzki Division for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University of Kiel, Kiel,
More information